PPARA and Alzheimer disease: In a mouse model of Alzheimer’s disease (AD), it has been demonstrated that SAHA is able to enhance the therapeutical activity of rosiglitazone, an agonist of the peroxisome proliferator-activated receptor (PPAR) family, already proposed as a promising drug in AD treatment [56].